Nurix Therapeutics (NRIX) Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Revenue data on file, last reported at $9.0 million in Q2 2026.

• On a quarterly basis, Revenue fell 79.47% year-over-year to $9.0 million in Q2 2026; TTM through May 2026 was $36.8 million, a 58.4% decrease from a year earlier, with the FY2025 full-year figure at $84.0 million, up 53.95% from the prior year.
• Revenue for Q2 2026 stood at $9.0 million, up from $6.3 million in the prior quarter.
• Over the last five years, Revenue for NRIX reached as high as $44.1 million in Q2 2025 and fell as low as $6.3 million in Q1 2026.
• Historically, Revenue has averaged $15.0 million across 5 years, with a median of $12.6 million in 2023.
• Across the five-year window, Revenue soared 264.34% in 2025 and sank 79.47% in 2026, its largest moves.
• Year by year, Revenue stood at $6.8 million in 2022, then jumped by 123.49% to $15.2 million in 2023, then decreased by 12.37% to $13.3 million in 2024, then rose by 2.21% to $13.6 million in 2025, then slumped by 33.39% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $9.0 million in Q2 2026, $6.3 million in Q1 2026, and $13.6 million in Q4 2025.